AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03523234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy
Description: etoposide with cisplatin/carboplatin, undergoing in prior to the surgery
Study NCT03523234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical surgery for stage II and IIIA small cell lung cancer (SCLC)
Description: Lobectomy/total lung resection plus mediastinal lymph node dissection.
Study NCT03523234 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: prophylactic cranial irradiation
Description: prophylactic cranial irradiation (PCI) undergoing with adjuvant chemotherapy simultaneously
Study NCT03523234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic cranial irradiation
Description: prophylactic cranial irradiation (PCI) undergoing with adjuvant chemotherapy simultaneously
Study NCT03523234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: etoposide with cisplatin/carboplatin
Study NCT03523234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: etoposide with cisplatin/carboplatin
Study NCT00891007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-mBN85B
Description: Low Dose arm, 1x 10E7 TCID50
Study NCT00891007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-mBN85B
Description: Normal Dose arm, 1x 10E8 TCID50
Study NCT00891007 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rouvax
Description: Standard measles vaccine, approved in South Africa
Study NCT01180647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended-Release Naltrexone
Description: 380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
Study NCT01180647 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motivational Enhancement Counseling
Description: The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
Study NCT03384888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Transcranial direct current stimulation Duration: 20 minutes; Intensity: 2 mA (miliamps); Placement of the electrodes: anode over the left M1 and cathode region over the right supraorbital region.
Study NCT03384888 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham Transcranial direct current stimulation The procedure is the same as for active tDCS, but the stimulation is non-active / sham.
Study NCT02715245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Description: Procedure/Surgery: Home-based rehabilitation In the patient's home, the primarily applied treatment has been physical therapy, seeking to achieve the highest possible functionality and gait training. In more than 25% of cases, health education is conducted for families and caregivers. Thus, consistent with the patient's condition and their tolerance to activity and to exercise their self-care independently, rehabilitation interventions are activated that prevent sequelae derived from functional limitations.
Study NCT00660751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: SNRIs
Study NCT00660751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: SNRIs
Study NCT02243969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed oil
Description: The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
Study NCT02243969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: high oleic sunflower oil (HOSF)
Description: The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
Study NCT01044706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50 mg Oral Tablet
Study NCT01044706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: 50 mg Oral Tablet
Study NCT03539146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary fiber
Description: Intake of yogurt containing cascara with 0%, 3%, 7%,13% dietary fiber in a crossover design.
Study NCT03539146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control yogurt
Description: Control yogurt
Study NCT01481181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc enriched water
Description: 3mg zinc/L of purified water from a filter installed in the households
Study NCT00847730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C. Negative Pressure Wound Therapy System
Description: This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an environment that promotes wound healing in chronic and acute wounds
Study NCT03317392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT03317392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03317392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03317392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04084366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-999
Description: For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
Study NCT04084366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-999
Description: For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
Study NCT01333579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
Study NCT03277950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality with feedback
Description: Individuals with stroke play game with correction of movement.
Study NCT03277950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality without feedback
Description: Individuals with stroke play game without correction of movement.
Study NCT03277950 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy
Description: Healthy do not play game
Study NCT00323622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: IM injection in the deltoid muscle
Study NCT03317392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03317392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT03317392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01120093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 100 μg bid
Description: Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
Study NCT03317392 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study NCT01120093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 200 μg bid
Description: Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
Study NCT03697213 — intervention group
Intervention type: OTHER
Intervention: Online study
Description: 20 hypothetical patient summaries
Study NCT02596035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02376036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD010
Description: MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
Study NCT01120093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidininum bromide 400 μg bid
Description: Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
Study NCT01120093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via inhalation in the morning and evening for 7 days
Study NCT01120093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol 12 μg bid
Description: Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days
Study NCT03637192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low altitude: 470m above sea level
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
Study NCT02376036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator.
Study NCT02376036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: Hepatitis A vaccine, inactivated
Study NCT02376036 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Hepatitis A vaccine, inactivated
Study NCT03350737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Description: Standard treadmill exercise session
Study NCT03350737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical rehabilitation
Description: Standard treadmill exercise session
Study NCT03350737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin i.v.
Study NCT03350737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% i.v.
Study NCT02129933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure.~\* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)
Study NCT02129933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared fluorescence endoscopy platform
Description: A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope to visualize the luminal wall. The fluorescent imaging will be performed prior and post the endoscopic resection (within the same endoscopic session)
Study NCT04480593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazilian Green Propolis Extract (EPP-AF)
Description: Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.
Study NCT04480593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard treatment includes, as needed, supplemental oxygen (non-invasive and invasive), antibiotics or antivirals, corticosteroids, vasopressor support, renal replacement therapy and extracorporeal membrane oxygenation (ECMO).
Study NCT02526680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrCam
Description: The OrCam low vision aid, camera attached to glasses, used by 27 glaucoma subjects for 1 month.
Study NCT03092557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of local pleural strain
Description: For each tidal volume, the local pleural strain will be determined over three consecutive respiratory cycles at four predetermined sites using lung ultrasonography.
Study NCT03637192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Säntis; 2500m above sea Level
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study NCT01839877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIA DEBIRI + systemic FOLFOX
Study NCT03709810 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Marketed Denture Adhesive (Super Poligrip Max Seal)
Description: The denture adhesive will be applied directly from the tubes. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.1 g for the maxillary and 0.6±0.1g for the mandibular dentures.
Study NCT03593070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Grief Management Intervention-Video
Description: The CGMI-V participant manual will be provided to participants either mailed or emailed. We will mail hard copies of the manual to caregivers who prefer them over the e-format. The technology assistant will review with each participant the use of technology Cisco WebEx and iPads) via e-mailed step-by-step written instructions and over-the-phone conferencing. Group sessions will take place using WebEx (an internet platform providing video connection) and iPads, at mutually agreed-upon times and days of the week. All group sessions will be audio and video-recorded for fidelity purposes, with caregivers' approval documented in the informed consent. The interventionists will label each recorded meeting group identification number, session number, and date.
Study NCT03709810 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Adhesive
Description: No adhesive will be applied.
Study NCT04709991 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular procedure
Description: Creation of a bone and arterial panorama using EndoNaut® software. The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.
Study NCT00323622 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: IM injection in the deltoid muscle
Study NCT00323622 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix®
Description: IM injection in the deltoid muscle
Study NCT00323622 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar™
Description: IM injection in the deltoid muscle
Study NCT03023982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 40 cc 0.25% of Bupivacaine Hydrochloride injection using ultrasound approach will be administered between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib
Study NCT03023982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: All blocks will be done under ultrasound
Study NCT00323622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine-pyrimethamine
Description: 1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
Study NCT03023982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracotomy
Description: The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.
Study NCT03023982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Description: The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.
Study NCT03023982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: standard pain control with opioids
Study NCT00067717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distance healing
Study NCT00067717 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Distance healing
Study NCT03023982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids
Description: standard pain control with opioids
Study NCT03023982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: standard pain control with NSAIDs
Study NCT03023982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: standard pain control with NSAIDs
Study NCT02488759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02488759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02488759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Study NCT02488759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Study NCT03914287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Myofascial release
Description: The Self-Myofascial release protocol for the lower limbs using a Foam Roller will include: Self-Myofascial release of the plantar region using and Solid Ball Massage; release of the myofascial components of the back of the leg using a Foam Roller; release of the myofascial components of the anterior part of the leg using a Foam Roller; release of myofascial components of the hamstring region using a Foam Roller; release of the myofascial components of the adductor muscles using a Solid Ball Massage in a sitting position; release of the myofascial components of the abductor muscles using a Foam Roller in lateral decubitus; and release of the myofascial components of the pelvitrochanteric muscles using a Foam Roller in a sitting position.
Study NCT06628544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Description: BCG vaccination
Study NCT06628544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin is administered on the day 0
Description: Metformin is administered on the day 0
Study NCT06628544 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06628544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin is administered on the day 9
Description: Metformin is administered on the day 9
Study NCT02367170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure
Description: Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation >92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
Study NCT02367170 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure
Description: Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation >92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
Study NCT06628544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin is administered on the day 85
Description: Metformin is administered on the day 85
Study NCT06631651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachioradialis release
Description: During distal radius fracture surgery (open reduction+internal fixation) partial brachioradialis release from the insertion of brachioradialis muscle was performed in order to perform reduction of fracture
Study NCT06631651 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Brachioradialis not released
Description: During distal radius fracture surgery (open reduction+internal fixation) brachioradialis release was not performed.
Study NCT02367170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
Study NCT02367170 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Midazolam
Description: In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.